MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-25-1513

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2025

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.

Sato Takami, Butler Marcus O, Piperno-Neumann Sophie, Hassel Jessica C, Nathan Paul, Shoushtari Alexander N, Rutkowski Piotr, Carvajal Richard D, Baurain Jean-Francois, Schlaak Max, Piulats Josep M, Sullivan Ryan J, Ochsenreither Sebastian, Dummer Reinhard, Kirkwood John M, Ikeguchi Alexandra, Joshua Anthony M, Middleton Mark R, Edukulla Ramakrishna, Pfeiffer Constance, Sacco Joseph J

СтатьяПеревод в очереди

Аннотация

PURPOSE: We conducted an integrated safety analysis from three clinical studies of tebentafusp, a first-in-class ImmTAC bispecific T-cell engager, which can redirect T cells to target glycoprotein 100-positive cells, in metastatic uveal melanoma.

EXPERIMENTAL

DESIGN

HLA-A*02:01-positive patients with unresectable or metastatic uveal melanoma enrolled in three clinical trials (IMCgp100-01, IMCgp100-102, and IMCgp100-202) who received ≥1 dose of tebentafusp were included. Safety data were pooled to evaluate the profile, onset, and management of treatment-related adverse events (TRAE). Adverse events of special interest included cytokine release syndrome (CRS), acute skin reactions (ASR), and liver function test elevations. Primary prophylaxis with medications was not permitted.

RESULTS

Among 410 tebentafusp-treated patients, the most common TRAE were pyrexia (77%), pruritus (71%), and chills (53%). Most patients experienced CRS (88%), almost always mild (grade 1, 19%) to moderate (grade 2, 67%) in severity, with only 2% experiencing grade 3 (n = 6) or 4 (n = 1) CRS. Additionally, 92% had at least one ASR, primarily pruritus and rash, with 21% having a grade 3 event. Onset of CRS and ASR was within 1 to 2 days of infusion and generally reversible with standard interventions. Elevated liver function tests were generally mild and resolved without intervention. Most TRAE occurred following the first few infusions and diminished in frequency and severity with repeated dosing; no cumulative TRAE were detected. Discontinuations due to TRAE were rare (2%); there were no treatment-related deaths.

CONCLUSIONS

TRAE were consistent with tebentafusp's mechanism of action, mostly occurred during dose escalation, and were predictable, reversible, and manageable with appropriate surveillance and intervention.

Для цитирования: Sato Takami, Butler Marcus O, Piperno-Neumann Sophie, Hassel Jessica C, Nathan Paul, Shoushtari Alexander N, Rutkowski Piotr, Carvajal Richard D, Baurain Jean-Francois, Schlaak Max, Piulats Josep M, Sullivan Ryan J, Ochsenreither Sebastian, Dummer Reinhard, Kirkwood John M, Ikeguchi Alexandra, Joshua Anthony M, Middleton Mark R, Edukulla Ramakrishna, Pfeiffer Constance, Sacco Joseph J. Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025. DOI: 10.1158/1078-0432.ccr-25-1513.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.